Cogent Submits NDA for Bezuclastinib in Advanced Systemic Mastocytosis
Event summary
- Cogent Biosciences submitted an NDA for bezuclastinib in Advanced Systemic Mastocytosis (AdvSM), based on APEX trial data showing a 65% ORR per mIWG criteria and 81% ORR per PPR criteria.
- The submission is the third for bezuclastinib in six months, with two other NDAs (PEAK and SUMMIT) under review and anticipated approvals in Q4 2026.
- Bezuclastinib demonstrated a well-tolerated safety profile with key adverse events including hair color change (31%), neutropenia (31%), and altered taste (28%).
- The APEX trial included 81 AdvSM patients, showing durable clinical activity with a 12-month PFS rate of 79% and a 12-month OS rate of 87%.
The big picture
Cogent's NDA submission for bezuclastinib in AdvSM marks a significant milestone in its strategy to develop precision therapies for rare, mutation-driven diseases. The company is rapidly advancing multiple regulatory filings, positioning itself as a key player in the targeted oncology space. With three NDAs under review and anticipated approvals later this year, Cogent is poised to potentially transform treatment options for patients with AdvSM and other KIT mutation-driven conditions.
What we're watching
- Regulatory Timing
- Whether the FDA will approve all three NDAs for bezuclastinib by Q4 2026 as anticipated.
- Clinical Efficacy
- How the durable clinical activity and well-tolerated safety profile of bezuclastinib will position it against existing treatments for AdvSM.
- Market Potential
- The pace at which Cogent can expand the use of bezuclastinib into other genetically defined diseases beyond AdvSM.
Related topics